Navigation Links
China Biologic Products Reports Higher Results for the First Quarter 2012
Date:5/8/2012

ided by operating activities was $8.2 million in the first quarter 2012, primarily from net income of $17.7 million, depreciation and amortization expenses of $1.9 million, less an increase in working capital (current assets minus current liabilities) of $10.3 million primarily due to higher direct sales to customers with longer periods for settling their accounts with us.

Net cash used in investing activities in the first quarter 2012 was $2.6 million, primarily for the acquisition of property, plant, and equipment and intangibles, and advances on non-current assets.

Net cash used in financing activities in the first quarter 2012 totaled $10.7 million, primarily for the $6.4 million repayment of a short-term bank loan and a $4.4 million dividend paid by our subsidiaries to the noncontrolling interest shareholders.

As a result, including the effects of foreign currency exchange rate changes on cash, China Biologic's cash decreased $4.4 million in the first quarter 2012. Cash totaled $85.0 million as of March 31, 2012.

As of March 31, 2012, total shareholders' equity was $150.4 million, working capital (current assets minus current liabilities) was $133.6 million, and the current ratio (current assets divided by current liabilities) was 3.5 times.

The Company believes it has sufficient cash on hand and continuing positive cash inflow from the sale of its plasma-based products in the Chinese market for its operations. Conference callChina Biologic will host a dial-in conference call at 8:00 a.m. EDT (New York) on May 9, 2012 (which is 8:00 p.m. in Beijing and Hong Kong on the same day), to discuss its results for the first quarter 2012. To participate in the conference call, please dial the appropriate number about 10 minutes prior to the scheduled conference call time.
The dial-in details for the live conference call are:

U.S. toll-free number+1 866 549 1292U.K. toll-free number+0 800 279 7818Mainland China toll-free n
'/>"/>

SOURCE China Biologic Products, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. China Biologic Products to Host Earnings Conference Call on May 9, 2012 at 8:00 a.m. EDT (NY)
2. ResearchMoz: Global and China 4A Zeolite Industry 2012 Deep Research Report - Market Research Report
3. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
4. CentraState and Freehold Radiology Group train physicians from China
5. Top buyers including Atico, Coles Group Asia, Kmart, Staples, Office Depot and Target Australia pre-registered to attend Global Sources spring China Sourcing Fairs
6. Professor Vishnu Chaturvedi of New York, USA Gives a Lecture at West China Hospital of Sichuan University
7. China Botanic Announces Results of Annual General Meeting
8. China Shenghuo Pharmaceutical Reports Financial Results for the Full Year 2011
9. ThermoGenesis Announces AABB Accreditation for Cord Blood Products Customer in China
10. Anaphore Announces Acquisition of RuiYi in Shanghai China for GPCR Biologics Drug Discovery Platform
11. Fi Asia-China, Hi & Ni China is Ready for Return on June 2012 in Shanghai
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 19, 2013 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... New England Journal of Medicine ( NEJM ) ... the investigational oral Bruton,s tyrosine kinase (BTK) inhibitor ibrutinib ... small lymphocytic lymphoma (SLL). Ibrutinib was shown to be ... SLL, even in patients who were at high-risk due ...
(Date:6/19/2013)... , June 19, 2013 The Physician-Patient Alliance for ... fatigue. The need to urgently address this issue ... Sentinel Event Alert #50 , "Medical device alarm safety in ... between January 2008 and June 2012, there were 98 alarm ... in death (82%) , 13 resulted in permanent loss ...
(Date:6/19/2013)... 2013   Voices Against Brain Cancer (VABC), ... brain cancer, today announced that it has awarded Tocagen ... clinical investigation of Toca 511 & Toca FC in ... cancer (Grade 3 or Grade 4).  Tocagen is a ... cancer, with an initial focus on brain cancer. ...
Breaking Medicine Technology:Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 2Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 3Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 4Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 5Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 6Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 2Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 3Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3
... LONG BRANCH, N.J., March 1, 2011 Pharma ChemOutsourcing today ... member companies of the USA,s various state biotechnology associations to ... would like to attend the September 12-15 show in New ... of hundreds of successful biotechnology companies over the past 12 ...
... Pharmaceuticals, Inc. (Nasdaq: OPTR ) today announced that ... Citi 2011 Global Health Care Conference on Thursday, March ... New York Hotel in New York City. Cowen and ... 2011 at 4:45 p.m. Eastern Time at The Boston Marriott ...
Cached Medicine Technology:Pharma ChemOutsourcing Targets BioNJ, PA Bio, MassBio, BayBio, SoCalBio, and NY Biotechnology Association Member Companies for September 2011 Show in New Jersey 2Optimer Pharmaceuticals to Present at March 2011 Investor Conferences 2
(Date:6/19/2013)... 2013 Chrysler made news recently when it ... 2.7 million Jeeps. The Jeep models in question are the ... according to the NHTSA are vulnerable to fire and explosion ... models are rear-mounted and have been alleged to catch fire ... Grand Cherokee with 32 rear-end crashes, which resulted in 44 ...
(Date:6/19/2013)... 19, 2013 Amber Roberson with ... Benefits, LLC, Native Care Health, LLC and Medcase, ... Health Underwriters’ (NAHU) new professional development course on ... This continuing education course for agents has been ... receive eleven education credits from the Missouri Department ...
(Date:6/19/2013)... New York, New York (PRWEB) June 19, 2013 ... involving pancreatitis and pancreatic cancer continue to mount in ... the U.S. Food & Drug Administration (FDA) recently held ... other diabetes drugs known as incretin mimetics. According ... may seek additional data from the makers of Januvia ...
(Date:6/19/2013)... Lawrence, KS (PRWEB) June 19, 2013 ... photographs is common with today’s computer software, it creates ... a form of misconduct. As an already published case ... of photo manipulation. , The Journal of Parasitology ... image manipulation in a 2004 article published in ...
(Date:6/19/2013)... by researchers at The University of Texas MD Anderson ... remarkable promise for the treatment of relapsed or refractory ... findings of the 18-center Phase 2 study were published ... . Previous interim findings were presented in December 2012 ... and Exposition. , Unprecedented results, fewer side ...
Breaking Medicine News(10 mins):Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 2Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 3Health News:RWI Benefits, LLC Becomes PPACA Certified 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2
... has increased its health budget by over 30 percent ... a new medical college//. ,"In a bid to ... medical education department budget to about Rs.1.52 billion. This ... billion," an official said. ,"The government not ...
... the June Journal of the American Society of Nephrology ... for chronic renal failure//. ,"Our results confirm an ... as an important causative factor in kidney disease," comments ... of the new study. ,Dr. Ejerblad and colleagues ...
... According to a new study by New York University School ... New York City are severely infected// with hepatitis B virus. ... the liver gets inflamed and can ultimately lead to cirrhosis ... 12 issue of Morbidity and Mortality Weekly, published by the ...
... new study, oral and intravenous antiviral drug may be ... ,Shingles, which is caused by varicella-zoster virus, is a ... at the University of Colorado and Health Sciences Center ... three women with moderate to severe pain following shingles. ...
... Middle school students have expressed a high degree of comfort ... schools are safer// , and make the students feel wanted. ... other schools. Psychologists from UCLA and UC ... than 70 sixth-grade classrooms in 11 Los Angeles public middle ...
... which is a severe form of food poisoning, now has ... team of researchers working at the University of Bristol//. ... researchers have narrowed down on a particular antibiotic called fosfomycin, ... effective in the laboratory, this drug has never been considered ...
Cached Medicine News:Health News:Kidney Failure three times pronounced with obesity 2Health News:Asian American Community Prone To Hepatitis B infection 2Health News:Asian American Community Prone To Hepatitis B infection 3Health News:Comfort Level, Maximum in Ethnically Diverse Schools 2Health News:Comfort Level, Maximum in Ethnically Diverse Schools 3
Indications For Usage: , Nasal surgery. , Ophthalmic surgery. , Facial surgery. , T&A surgery. ...
The Cuffed Endoflex endotracheal tube had a murphy eye, high volume, low pressure cuff., ,Endoflex endotracheal tubes are individual packaged in sterilized pouches, 10 units per box, 10 boxes pe...
... The new Level 1 H-1200 Fast Flow ... builds on the benefits of the existing Level ... Level 1 H-1200 Fast Flow Fluid Warmer incorporates ... clamping capability, while continuing to deliver warm fluids ...
Futuremeds Astotherm Plus Blood and Fluid Warmers meet American Blood Bank and ECRI standards., ,Astotherm is a durable warmer you can rely on for many years....
Medicine Products: